Scholar Rock Holding Corp
$ 46.97
-0.11%
25 Feb - close price
- Market Cap 4,791,290,000 USD
- Current Price $ 46.97
- High / Low $ 47.92 / 46.78
- Stock P/E N/A
- Book Value 2.47
- EPS -3.15
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -2.18 %
- 52 Week High 49.82
- 52 Week Low 22.71
About
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$50.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-06 | 2025-05-05 | 2025-03-17 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 | 2023-05-09 | 2023-03-07 |
| Reported EPS | -0.9 | -0.98 | -0.67 | -0.61 | -0.6644 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 | -0.49 | -0.46 |
| Estimated EPS | -0.84 | -0.66 | -0.7076 | -0.6288 | -0.6 | -0.61 | -0.51 | -0.49 | -0.52 | -0.56 | -0.58 | -0.57 |
| Surprise | -0.06 | -0.32 | 0.0376 | 0.0188 | -0.0644 | 0.01 | -0.08 | -0.01 | -0.01 | 0.09 | 0.09 | 0.11 |
| Surprise Percentage | -7.1429% | -48.4848% | 5.3137% | 2.9898% | -10.7333% | 1.6393% | -15.6863% | -2.0408% | -1.9231% | 16.0714% | 15.5172% | 19.2982% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.86 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2026-02-25 23:52:45
Mo Qatanani, Chief Scientific Officer at Scholar Rock Holding Corp (SRRK), sold 8,484 shares of the company on February 23, 2026, reducing his holdings to 98,445 shares. This transaction is part of a pattern where insiders have sold significantly more shares than they have bought over the past year. Shares were trading at $47.07 on the day of the sale, with the company having a market cap of $4.791 billion.
2026-02-25 15:52:45
Scholar Rock Holding (SRRK) has seen strong recent share performance but its valuation is under scrutiny. While its Price-to-Book ratio of 19.6x suggests overvaluation compared to peers, a Discounted Cash Flow model indicates the stock could be trading well below its estimated future cash flow value. Investors are advised to consider clinical trial risks and ongoing losses alongside these differing valuation perspectives.
2026-02-22 18:41:21
Redmile Group, LLC significantly increased its stake in Scholar Rock Holding Corporation, buying 1,316,390 shares worth an estimated $49.37 million. This investment boosts Redmile Group's position to 16.94% of its reportable assets under management. Scholar Rock's shares have climbed 25.7% over the past year, indicating investor confidence ahead of a planned Biologics License Application resubmission for apitegromab.
2026-02-20 00:00:00
Scholar Rock's General Counsel, Junlin Ho, sold 9,580 shares of the company's stock on February 17th for approximately $445,757, reducing their ownership by 3.81%. This follows a previous sale of 8,016 shares in January. The company (NASDAQ:SRRK) has a market capitalization of $4.87 billion, a consensus "Buy" rating from analysts with an average target price of $51.14, and high institutional ownership.
2026-02-18 13:28:11
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on rare neuromuscular diseases, announced that its management will participate in three upcoming investor conferences in March 2026. The company will hold fireside chats at the TD Cowen 46th Annual Health Care Conference, the Leerink Partners 2026 Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference. Live webcasts and replays of these events will be available on Scholar Rock's investor relations website.
2026-02-13 20:57:45
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards consisting of 114,668 shares to seven new employees. These awards include stock options for 64,226 shares and restricted stock units for 50,442 shares, granted under the company's 2022 Inducement Equity Plan. The grants aim to attract new talent and align their interests with the company's performance, as per Nasdaq Listing Rule 5635(c)(4).
